Ociperlimab plus tislelizumab demonstrated modest preliminary antitumor activity as treatment for patients with locally advanced or metastatic, CPI-experienced NSCLC.

Clinical activity of this combination was shown by an ORR of 8.0%, with two patients experiencing PRs, a disease control rate of 56%, and median PFS of almost 4 months.

The combination of ociperlimab plus tislelizumab was generally well tolerated with an acceptable safety profile.

In the ongoing phase 1/1b, open-label AdvanTIG-105 dose-escalation/expansion study (NCT04047892), ociperlimab plus tislelizumab showed preliminary antitumor activity and was well tolerated in patients with advanced solid tumors.2,5-10

Safety
- Overall, 23 patients (88.5%) experienced ≥1 treatment-emergent adverse event (TEAE), 11 (42.3%) had ≥3 TEAEs, and nine (34.6%) had serious TEAEs (Table 2).
- The most common (in ≥20% of patients) TEAEs were fatigue (30.8%), cough (26.9%), and rash (23.1%).
- Immune-mediated TEAEs were reported in 10 patients (38.5%), of whom three (11.5%) experienced grade 3 events
- Immune-mediated grade 3 events included rash, immune-mediated lung disease, and immune-mediated dermatisms, in one (3.8%) patient each.